Production (Stage)
Zevra Therapeutics, Inc.
ZVRA
$8.65
$0.080.93%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -86.01% | -129.13% | -339.38% | -301.09% | -29.72% |
| Total Depreciation and Amortization | 160.18% | 535.09% | 965.13% | 364.68% | 159.81% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1,343.47% | 541.72% | 236.58% | 129.43% | -69.86% |
| Change in Net Operating Assets | -956.74% | -212.87% | -136.68% | 35.37% | -113.39% |
| Cash from Operations | -35.19% | -107.74% | -218.57% | -135.46% | -137.68% |
| Capital Expenditure | 62.92% | -- | 72.09% | -114.04% | -151.89% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -115.76% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -157.67% | -266.54% | 187.72% | -31.93% | 225.93% |
| Cash from Investing | -276.57% | -27.44% | 78.23% | -215.08% | 129.66% |
| Total Debt Issued | 95.21% | 37.51% | 59.03% | 538.18% | 14.03% |
| Total Debt Repaid | -790.91% | -138.29% | -246.78% | -230.58% | 66.39% |
| Issuance of Common Stock | 802.00% | 963.54% | 22,091.74% | 2,766.79% | 2,227.47% |
| Repurchase of Common Stock | -- | -- | 100.00% | 100.00% | 100.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -3,175.00% | -3,175.00% | -- |
| Cash from Financing | 146.77% | 188.46% | 272.00% | 1,479.80% | 258.13% |
| Foreign Exchange rate Adjustments | 292.42% | 931.82% | 213.79% | 52,000.00% | -124.54% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -306.48% | 58.67% | 140.20% | -154.52% | 104.44% |